65797-52-6

Usage

Uses

Used in Pharmaceutical Industry:
1,1,1,3,3,3-Hexafluoro-2-(1,2,3,4-tetrahydro-quinolin-6-yl)-propan-2-ol is used as a therapeutic agent for the treatment of chronic pain conditions. Its ability to selectively block the Nav1.8 voltage-gated sodium channel makes it a potential candidate for the development of new analgesic drugs, offering a targeted approach to pain management.
Used in Research:
1,1,1,3,3,3-Hexafluoro-2-(1,2,3,4-tetrahydro-quinolin-6-yl)-propan-2-ol is used as a research tool to study the role of the Nav1.8 channel in pain modulation. Understanding the function of this channel can help in the development of targeted pain management strategies and the discovery of new therapeutic agents for chronic pain conditions.

Upstream product

• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 684-16-2 Hexafluoroacetone 
• 920-66-1 1,1,1,3',3',3'-hexafluoro-propanol 
• 7440-44-0 pyrographite 
• 65797-60-6 2-(1-acetoacetyl-1,2,3,4-tetrahydro-quinolin-6-yl)-1,1,1,3,3,3-hexafluoro-propan-2-ol 

Relevant academic research and scientific papers

Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORγ/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity

We disclose the optimization of a high throughput screening hit to yield benzothiazine and tetrahydroquinoline sulfonamides as potent RORγt inverse agonists. However, a majority of these compounds showed potent activity against pregnane X receptor (PXR) and modest activity against liver X receptor α (LXRα). Structure-based drug design (SBDD) led to the identification of benzothiazine and tetrahydroquinoline sulfonamide analogs which completely dialed out LXRα activity and were less potent at PXR. Pharmacodynamic (PD) data for compound 35 in an IL-23 induced IL-17 mouse model is discussed along with the implications of a high Ymax in the PXR assay for long term preclinical pharmacokinetic (PK) studies.

Copper(II)-Catalysed Aerobic Oxidative Coupling of Arylamines with Hexafluoroisopropanol: An Alternative Methodology for Constructing Fluorinated Compounds

The selective functionalisation of arylamine derivatives with hexafluoroisopropanol through copper(II)-catalysed aerobic oxidative coupling was developed to generate various fluoroalkylated arylamines under mild conditions. This method has a wide substrat

Cobalt-Catalyzed Selective Functionalization of Aniline Derivatives with Hexafluoroisopropanol

A cobalt-catalyzed site-selective functionalization of aniline derivatives with hexafluoroisopropanol, which enables the synthesis of a wide array of fluoroalkylated anilines, a class of highly valuable building blocks for further preparation of fluorinated functional products, is reported. The developed transformation proceeds with operational simplicity, use of earth-abundant metal catalyst, broad substrate scope, good functional group tolerance, and mild reaction conditions.

Discovery and optimization of a novel series of liver X receptor-α agonists

A novel series of hexafluorocarbinols were discovered as potent activators of the liver X receptor-α using a fluorescence polarization assay. Structure-activity relationship study led to the identification of compounds that are more potent agonists than t

ANILINO LIVER X-RECEPTOR MODULATORS

The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.

Polyfluorohydroxyisopropyl-heterocyclic compounds

Polyfluorohydroxyisopropyl: -indolines, -tetrahydroquinolines, and -benzazepines, such a α,α-bis(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-6-methanol, useful as intermediates for antihypertensives.

Antihypertensive polyfluorohydroxyisopropyl bicyclic and tricyclic carbostyrils

Polyfluorohydroxyisopropyl bicyclic and tricyclic carbostyrils, such as 1,2-dihydro-8-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-6-methyl-4H-pyrrolo-[3,2,1-ij]quinolin-7-one, useful as antihypertensive agents.